NCT06541860View on ClinicalTrials.gov

DAratumumab and REvlimid REfractory MM

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

February 21, 2028

Study Completion Date

August 21, 2028

Conditions
Multiple Myeloma
Trial Locations (1)

27100

RECRUITING

Irccs San Matteo Pavia, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER